SUBSCRIBE
SUBSCRIBE
News   Drug Development

Phynova Obtains FDA Approval Of Its IND To Enter Into A Clinical Trial Of PYN17 For The Treatment Of Chronic Hepatitis C

January 8, 2007 | 
1 min read
Phynova Group PLC (AIM: PYN), a developer of pharmaceuticals derived from Chinese botanical drugs targeting viral and metabolic diseases and cancer, is pleased to announce the introduction of its first drug candidate into clinical trials in the US.
Clinical research Phase 1 Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Lung organ anatomy symbol for health and medical illustrations. vector, illustration.
Antibody-drug conjugate (ADC)
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
May 22, 2026
 · 
3 min read
 · 
Annalee Armstrong
Electricity saving, ecology awareness or reduce electric cost and expense concept, man pulling electric cord to unplug to save money or for ecology power.
Parkinson’s disease
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop
May 22, 2026
 · 
2 min read
 · 
Tristan Manalac
Human liver organ and pills. World hepatitis day. National liver health awareness month. Liver transplantation, donation background. Save patient life in hospital with liver transplant
Postmarket research
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
May 21, 2026
 · 
3 min read
 · 
Tristan Manalac
Crowd silhouettes reach toward a raised trophy beneath a vivid sunset sky, showing shared ambition, victory, teamwork, celebration, and success with open space for text.
Weight loss
Lilly’s triple agonist shows bariatric surgery–like weight loss results
May 21, 2026
 · 
3 min read
 · 
Annalee Armstrong